Evaluation of the benefit of the Health care reimbursement for the new generation of NSAIDs(COX-2 selective NSAIDs) via retrospective analysis using data warehouse of BNHI Taiwan.
碩士 === 長庚大學 === 醫務管理學研究所 === 95 === A new-generation non-steroid anti-inflammatory agent, known as COX-2, was introduced in 1998. This agent, according to clinical studies, produces a lower level of gastrointestinal toxicity than most conventional therapies and has soon become a popular treatment in...
Main Authors: | HUANG, YEU-JIUN, 黃宇君 |
---|---|
Other Authors: | Ji-Tian Sheu |
Format: | Others |
Language: | zh-TW |
Published: |
2007
|
Online Access: | http://ndltd.ncl.edu.tw/handle/24730536060056057305 |
Similar Items
-
Study of COX-independentchemopreventive activity ofNSAIDs : NSAIDs chemopreventive action
by: Tofiq, Shokhan
Published: (2015) -
Design and Development of Novel Injectable COX-2 NSAIDs
by: Yen-Ling Cheng, et al.
Published: (2005) -
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors
by: Alaa Rostom, et al.
Published: (2009-10-01) -
Structural and thermal characterisation of NSAIDs and cyclodextrin-NSAID complexes
by: Dean, Pamela Mary
Published: (2014) -
NSAID enteropathy
by: E. N. Kareva
Published: (2020-02-01)